Press Release
On August 1, 2024 the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) approved the Marketing Authorization Transfer of REDEVANT® from Eli Lilly and Company to Kowa Company, Ltd.
Redevant’s indication is Hypocholesterolemic in Mexico, in other words, Redevant® helps lower cholesterol and triglyceride (fat) levels.
Global Regulatory Partners Mexico LLC, is the designed local representative appointed by KOWA Inc for REDEVANT® in Mexico.
About Global Regulatory Partners Group
Global Regulatory Partners, Inc (GRP) is a global provider of tailored clinical development, regulatory affairs, quality and pharmacovigilance services for pharma, biotech, medical devices and cosmetic industries worldwide.
Global Regulatory Partners. Inc, has now over 500 employees, 6 affiliates in 6 countries (USA, Brazil, Mexico, Japan, China and South Korea) and more than 500 satisfied clients worldwide.
In China, GRP-China has offices in three locations, Shanghai, Beijing and Hainan, and has local teams of Regulatory Affairs, Clinical Development ,Quality and Pharmacovigilance professionals, who support the clinical development and products’ registration of many pharmaceutical and medical device companies in Hainan pilot zone and in China Mainland as well.